Infectious Disease Control

Novavax to Participate in World Vaccine Congress Europe

GAITHERSBURG, Md., Oct. 16, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a...

2021-10-16 04:39 4391

Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine

TAIPEI, Oct. 15, 2021 /PRNewswire/ -- The Lancet Respiratory Medicine , one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics (...

2021-10-15 18:36 3123

Interim Results Of A Pioneering Combination Study In Argentina With More Than 1,000 Participants Confirm The One-shot Sputnik Light Vaccine (The First Component Of The Sputnik V Vaccine) Is An Effective Universal Booster For Vaccines Produced By AstraZeneca, Sinopharm, Moderna And Cansino Inducing Strong Immune Response And Showing High Safety Profile. Combination Of AstraZeneca And Sputnik Light Vaccines Showed High Immunogenicity Results.

* One-shot Sputnik Light is the first component of the Sputnik V vaccine, the world's first registered vaccine against coronavirus. Sputnik V pioneered the heterogeneous boosting approach (a "vaccine cocktail" using human adenovirus serotype 26 as the first component and human adenovirus seroty...

2021-10-15 05:26 2316

More community healthcare needed in COVID-19 planning as chronic disease rates pressure hospitals

* Allied health experts call for more community-based care models to cope with COVID surge * 'Long COVID' shown to affect one in four people who catch the virus, leading to an increase in chronic disease sufferers and the need for more rehabilitation services. The UK now has two million cases...

2021-10-13 05:00 1736

Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease

DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health...

2021-10-09 03:07 5519

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, N.C., Oct. 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported new data from the opaganib global Phase 2/3 study in hospitalized patien...

2021-10-04 21:24 10297

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 3491

Impact Credit Solutions and Bank Central Asia partner to offer financing to the Indonesian healthcare sector

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- Bank Central Asia (BCA), a leading Indonesian commercial bank, and Impact Credit Solutions (ICS) have partnered to offer affordable financing to the Indonesian healthcare sector during the COVID-19 pandemic. BCA has committed toparticipating in the US$40 ...

2021-09-30 09:00 2467

Zymo Research Pays it Forward With Their Commitment to Eradicate the COVID-19 Pandemic in India

DNA/RNA Shield – DirectDetect™ reagent eliminates RNA extraction for rapid deployment of COVID-19 tests in affected countries IRVINE, Calif., Sept. 28, 2021 /PRNewswire/ -- Zymo Research has donated one million COVID-19 test kits that include its newDNA/RNA Shield - DirectDetect™ reagent and col...

2021-09-28 14:57 2298

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2021-09-28 08:00 3808

LEAD Horizon: How travelers in Austria gargle against the corona virus

Austrian success model with gold standard tests is possible worldwide VIENNA, Sept. 27, 2021 /PRNewswire/ -- Vienna got through the pandemic better in comparison to other European cities - thanks to a specially developed PCR test by the Austrian company LEAD Horizon, which is already used in 13 ...

2021-09-27 09:00 2509

Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that onSeptember 22 the Brazilian Health Regulatory Agency (ANVISA) ...

2021-09-26 23:09 5887

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses - NanoFlu was well-tolerated with a comparable safety profile...

2021-09-24 08:47 4807

/C O R R E C T I O N -- pHOXBIO/

In the news release, pHOXBIO Announces Breakthrough Clinical Trial Results Concluding Prophylactic Nasal Spray Prevents Infection from SARS-CoV-2, issued Sept. 22, 2021 by pHOXBIO over PR Newswire, we are advised by the company that the hyperlinks have been revised. The complete, corrected releas...

2021-09-24 02:42 2212

Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine

* Novavax and Serum Institute of India file regulatory submission for World Health Organization Emergency Use Listing of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedic...

2021-09-23 21:59 6601

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins

- Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), a...

2021-09-23 15:00 5665

INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico

News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...

2021-09-22 20:00 5214

Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest

* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...

2021-09-22 18:56 1820

Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug

SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation ...

2021-09-22 18:45 5222

The International Standard Proposed by Experts from BMC Medical in Terms of High-flow Respiratory Therapy Equipment Officially Released

BEIJING, Sept. 22, 2021 /PRNewswire/ -- The international standard for high-flow respiratory therapy equipment (standard number: ISO 80601-2-90:2021) proposed by BMC Medical standardization technical experts has been formally released recently on the official websites of the International Organiz...

2021-09-22 15:00 2969
1 ... 23242526272829 ... 79

Week's Top Stories